Praziquantel 600 mg Section 19A Approval – Now Available from Pro Pharmaceuticals Group

Update – PBS relisting effective 1 January

Praziquantel 600 mg tablets have now been formally relisted on the Pharmaceutical Benefits Scheme (PBS) effective 1 January.

This relisting supports a return to community-based management of schistosomiasis via GP prescribing and community pharmacy dispensing, reducing the need for ongoing hospital-funded supply.

PBS item: 15199Y

Further details are available on the PBS website:https://www.pbs.gov.au/medicine/item/15199Y

Pro Pharmaceuticals Group continues to support supply of Praziquantel Tablets, USP 600 mg (Endo, USA) in Australia under the TGA Section 19A pathway.

_______________________________________________________________

Dear Healthcare Professional,

Discontinuation of BILTRICIDE® (Praziquantel 600 mg tablets, AUST R: 18845)

Pro Pharmaceuticals Group acknowledges the discontinuation of the Australian registered product BILTRICIDE® (Praziquantel 600 mg tablet bottle, AUST R: 18845).

To support ongoing patient care and minimise disruption, Pro Pharmaceuticals Group has secured supply of an alternative product – Praziquantel tablets, USP 600 mg (Endo, USA) – under approval granted by the TGA in accordance with Section 19A of the Therapeutic Goods Act 1989.

This Section 19A approval is valid until 31 March 2027.

Key details:

• Active ingredient and strength are identical to the discontinued Australian product.

• Registered and marketed in the United States; labelled in English.

• Approved for use in the treatment of schistosoma infections (Schistosoma haematobium, S. japonicum, S. mekongi, S. mansoni).

• Supplied in packs of 6 tablets.

We encourage hospital pharmacies, infectious diseases units, and community pharmacists to share this information internally and contact us regarding supply.

📧 For orders or further enquiries, please email: orders@propg.com.au🌐 Or visit: www.propg.com.au